Teva Takes Aim At First Truvada And Atripla Generics In US
Israeli Firm Set For ‘Some Exclusivity’
Teva has secured one of the largest tablet formulation opportunities in the US with the launch of the first generics to Gilead Sciences’ Truvada, including for HIV-1 PrEP, at the same time introducing a version of the triple-combination Atripla. Collectively the brands had sales north of $3bn last year.
